<DOC>
	<DOC>NCT01173120</DOC>
	<brief_summary>The purpose of this study is to determine the safety and acceptability of a device used in place of traditional syringes for abatacept self-injection.</brief_summary>
	<brief_title>Methotrexate - Inadequate Response Device Sub-Study</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Men and women, ages â‰¥ 18 Participants who are considered methotrexate inadequate responders (MTXIR) 10 or more swollen joints (66 joint count) and 12 or more tender joints (68 joint count) Participants were to have been enrolled in the main MTXIR study and been treated with open label abatacept for at least 3 months in the long term period Participants who failed one or multiple antitumor necrosis factor (TNF) therapies Participants who meet diagnostic criteria for any other rheumatic disease (e.g., lupus erythematosus) Participants with active vasculitis of a major organ system (except for subcutaneous rheumatoid nodules) Participants with severe chronic or recurrent bacterial infections Participants who have received treatment with rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>